Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LNPEP | Q9UIQ6 | 3/20 | 0.59 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.59 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.57 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.53 |
| ▸ | NPY1R | P25929 | 1/20 | 0.51 |
| ▸ | NPY2R | P49146 | 1/20 | 0.51 |
| ▸ | NPY4R | P50391 | 1/20 | 0.51 |
| ▸ | YARS1 | P54577 | 2/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31025663 | 1.00 | LNPEP (0.59) | LNPEPERAP2NAALAD2FOLH1NPY1R | |
| SCHEMBL30090915 | 0.94 | LNPEP (0.64) | LNPEPERAP2NPY1RNPY2RNPY4R | |
| SCHEMBL31710009 | 0.94 | NAALAD2 (0.58) | LNPEPERAP2NAALAD2FOLH1NPY1R | |
| SCHEMBL285712 | 0.94 | NAALAD2 (0.58) | LNPEPERAP2NAALAD2FOLH1NPY1R | |
| SCHEMBL29854734 | 0.94 | NAALAD2 (0.58) | LNPEPERAP2NAALAD2FOLH1NPY1R | |
| SCHEMBL29693799 | 0.94 | NAALAD2 (0.58) | LNPEPERAP2NAALAD2FOLH1NPY1R | |
| SCHEMBL4417821 | 0.94 | LNPEP (0.59) | LNPEPERAP2NAALAD2NPY1RNPY2R | |
| SCHEMBL4417844 | 0.94 | LNPEP (0.59) | LNPEPERAP2NAALAD2NPY1RNPY2R | |
| SCHEMBL30178189 | 0.93 | LNPEP (0.51) | LNPEPERAP2NAALAD2NPY1RNPY2R | |
| SCHEMBL30974007 | 0.92 | ERAP2 (0.52) | LNPEPERAP2NAALAD2NPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326814-A1 | MODIFIED OXYNTOMODULIN AND METHODS OF USE THEREOF | OPKO BIOLOGICS LTD. (IL) | 2025-10-23 | — | — | US | claimed |
| US-20250326814-A1 | MODIFIED OXYNTOMODULIN AND METHODS OF USE THEREOF | OPKO BIOLOGICS LTD. (IL) | 2025-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326814-A1 | MODIFIED OXYNTOMODULIN AND METHODS OF USE THEREOF | OGFRL1, OXGR1, THOP1 | LNPEP 1358/4885ERAP2 1121/4885NAALAD2 3714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.